NACDS adds new specialty pharmacy session to Regional Chain Conference agenda
ALEXANDRIA, Va. — The National Association of Chain Drug Stores has expanded its program lineup for the upcoming 2013 Regional Chain Conference to now include a new session of specialty pharmacy.
The conference will take place Feb. 3 to 5 in Fort Lauderdale, Fla., and is designed to address the challenges facing senior retail executives who operate up to 250 stores.
The new "Developing Specialty Pharmacy" session is scheduled to take place on Feb. 3 and will be presented by Gary Cohen, CEO of the National Association of Specialty Pharmacy, and Michael Nameth, acting executive director of NASP and CEO of Town Total Health.
FDA approves Wockhardt epilepsy drug
PARSIPPANY, N.J. — The Food and Drug Administration has approved a generic epilepsy drug made by Wockhardt, the company said.
Wockhardt, based in India, announced the approval of lamotrigine extended-release tablets in the 25-mg, 50-mg, 100-mg, 200-mg and 300-mg strengths.
The drug is a generic version of GlaxoSmithKline’s Lamictal XR. The U.S. market for the drug is about $250 million, according to IMS Health.
FDA approves Bayer IUD
WAYNE, N.J. — The Food and Drug Administration has approved a new intrauterine device for preventing pregnancy made by Bayer HealthCare Pharmaceuticals, the drug maker said.
Bayer announced the approval of Skyla (levonorgestrel-releasing uterine system), which can prevent pregnancy for up to three years. The IUD contains 13.5 mg of levonorgestrel.
Nearly 50% of pregnancies in the United States are unintended, according to the National Center for Health Statistics.